MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 565083 | Name: M-COPA

Description:

WARNING: This product is for research use only, not for human or veterinary use.

M-COPA is a golgi disruptor which inhibits cell surface expression of MET protein and the ADP-ribosylation factor 1 (Arf1) activation. M-COPA also inhibits angiogenesis through suppression of both VEGFR1/2 and nuclear factor-kappaB (NF-kappaB) signaling pathways.

Chemical Structure

M-COPA
M-COPA
CAS#861718-91-4

Theoretical Analysis

MedKoo Cat#: 565083

Name: M-COPA

CAS#: 861718-91-4

Chemical Formula: C25H34N2O2

Exact Mass: 394.2620

Molecular Weight: 394.56

Elemental Analysis: C, 76.10; H, 8.69; N, 7.10; O, 8.11

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
M-COPA; MCOPA; M COPA; AMF26; AMF 26; AMF-26; 2-Methylcoprophilinamide; 2 Methylcoprophilinamide
IUPAC/Chemical Name
(2E,4E)-5-[(1S,2S,4aR,6R,7S,8S,8aS)-7-Hydroxy-2,6,8-trimethyl-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]-2-methyl-N-(pyridin-3-ylmethyl)penta-2,4-dienamide
InChi Key
JQPHOWVAGGEOKI-VXBYPBBWSA-N
InChi Code
InChI=1S/C25H34N2O2/c1-16-10-11-21-13-18(3)24(28)19(4)23(21)22(16)9-5-7-17(2)25(29)27-15-20-8-6-12-26-14-20/h5-12,14,16,18-19,21-24,28H,13,15H2,1-4H3,(H,27,29)/b9-5+,17-7+/t16-,18+,19-,21-,22-,23-,24-/m0/s1
SMILES Code
O=C(NCC1=CC=CN=C1)/C(C)=C/C=C/[C@H]2[C@@H](C)C=C[C@@]3([H])C[C@@H](C)[C@H](O)[C@@H](C)[C@]23[H]
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 394.56 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Alborzinia H, Ignashkova TI, Dejure FR, Gendarme M, Theobald J, Wölfl S, Lindemann RK, Reiling JH. Golgi stress mediates redox imbalance and ferroptosis in human cells. Commun Biol. 2018 Nov 28;1:210. doi: 10.1038/s42003-018-0212-6. eCollection 2018. PubMed PMID: 30511023; PubMed Central PMCID: PMC6262011. 2: Ohashi Y, Okamura M, Katayama R, Fang S, Tsutsui S, Akatsuka A, Shan M, Choi HW, Fujita N, Yoshimatsu K, Shiina I, Yamori T, Dan S. Targeting the Golgi apparatus to overcome acquired resistance of non-small cell lung cancer cells to EGFR tyrosine kinase inhibitors. Oncotarget. 2017 Dec 6;9(2):1641-1655. doi: 10.18632/oncotarget.22895. eCollection 2018 Jan 5. PubMed PMID: 29416720; PubMed Central PMCID: PMC5788588. 3: Obata Y, Horikawa K, Shiina I, Takahashi T, Murata T, Tasaki Y, Suzuki K, Yonekura K, Esumi H, Nishida T, Abe R. Oncogenic Kit signalling on the Golgi is suppressed by blocking secretory trafficking with M-COPA in gastrointestinal stromal tumours. Cancer Lett. 2018 Feb 28;415:1-10. doi: 10.1016/j.canlet.2017.11.032. Epub 2017 Nov 28. PubMed PMID: 29196126. 4: Benabdi S, Peurois F, Nawrotek A, Chikireddy J, Cañeque T, Yamori T, Shiina I, Ohashi Y, Dan S, Rodriguez R, Cherfils J, Zeghouf M. Family-wide Analysis of the Inhibition of Arf Guanine Nucleotide Exchange Factors with Small Molecules: Evidence of Unique Inhibitory Profiles. Biochemistry. 2017 Sep 26;56(38):5125-5133. doi: 10.1021/acs.biochem.7b00706. Epub 2017 Sep 13. PubMed PMID: 28858527. 5: Hara Y, Obata Y, Horikawa K, Tasaki Y, Suzuki K, Murata T, Shiina I, Abe R. M-COPA suppresses endolysosomal Kit-Akt oncogenic signalling through inhibiting the secretory pathway in neoplastic mast cells. PLoS One. 2017 Apr 12;12(4):e0175514. doi: 10.1371/journal.pone.0175514. eCollection 2017. PubMed PMID: 28403213; PubMed Central PMCID: PMC5389679. 6: Hattori T, Watanabe-Takahashi M, Shiina I, Ohashi Y, Dan S, Nishikawa K, Yamori T, Naito M. M-COPA, a novel Golgi system disruptor, suppresses apoptosis induced by Shiga toxin. Genes Cells. 2016 Aug;21(8):901-6. doi: 10.1111/gtc.12386. Epub 2016 Jun 15. PubMed PMID: 27302278. 7: Ohashi Y, Okamura M, Hirosawa A, Tamaki N, Akatsuka A, Wu KM, Choi HW, Yoshimatsu K, Shiina I, Yamori T, Dan S. M-COPA, a Golgi Disruptor, Inhibits Cell Surface Expression of MET Protein and Exhibits Antitumor Activity against MET-Addicted Gastric Cancers. Cancer Res. 2016 Jul 1;76(13):3895-903. doi: 10.1158/0008-5472.CAN-15-2220. Epub 2016 Apr 12. PubMed PMID: 27197184.